Optimizing Drug Dosing in Diabetic Kidney Disease

Sep 8, 2026 · Published in: Expert Opinion on Drug Metabolism & Toxicology

Background Information

Tailored dosing strategies are key in diabetic kidney disease drug therapy.

Understanding pharmacokinetics in diabetic kidney disease (DKD) is crucial for optimizing treatment with newer therapies and preventing adverse effects. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and endothelin receptor antagonists (ERA) show exposure changes in reduced kidney function, while newer incretin therapies remain stable. Pharmacokinetic variability in DKD necessitates drug-specific dosing considerations over universal therapeutic drug monitoring to ensure safety and efficacy. Tailored dosing based on individual patient factors is essential for optimal drug therapy in DKD.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Mousavi T, Shaya FT, Munir KM, Davis SN

Citation: Mousavi T, Shaya FT, Munir KM, et al. Pharmacokinetics of novel drugs for the treatment of Diabetic nephropathy. Expert opinion on drug metabolism & toxicology. 2026. doi:10.1080/17425255.2026.2729203

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

Deep Analysis Pending

The full analysis for this article is being written and reviewed. Every analysis is checked by a licensed pharmacist before it publishes.